Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix-IPV+Hib booster safety study in healthy Vietnamese toddlers
2013-002538-18Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Infanrix-IPV + Hib in diphtheria, Tetanus, pertussis and 2 more, sponsored by GSK. Primary endpoints: Safety and reactogenicity after booster vaccination, Solicited symptoms and 2 more.
02
Drugs
Infanrix-IPV + Hib
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2013-002538-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002538-18.